{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T06:44:04Z","timestamp":1759041844610},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,5,1]]},"DOI":"10.2146\/ajhp130471","type":"journal-article","created":{"date-parts":[[2014,4,14]],"date-time":"2014-04-14T20:50:52Z","timestamp":1397508652000},"page":"728-738","source":"Crossref","is-referenced-by-count":25,"title":["Polypharmacy with antipsychotic drugs in patients with schizophrenia: Trends in multiple health care systems"],"prefix":"10.1093","volume":"71","author":[{"given":"FangFang","family":"Sun","sequence":"first","affiliation":[{"name":"Center for Applied Health Research, Temple, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen M.","family":"Stock","sequence":"additional","affiliation":[{"name":"Center for Applied Health Research, and Assistant Professor, College of Medicine, Texas A&M Health Sciences Center, Bryan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurel A.","family":"Copeland","sequence":"additional","affiliation":[{"name":"Central Texas Veterans Health Care System, Temple, and Associate Director, Center for Applied Health Research, and Associate Professor, College of Medicine, Texas A&M Health Sciences Center."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John E.","family":"Zeber","sequence":"additional","affiliation":[{"name":"Health Outcomes Core (jointly sponsored by Central Texas Veterans Health Care System and Scott & White Healthcare), Temple, and Associate Professor, College of Medicine, Texas A&M Health Sciences Center."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian K.","family":"Ahmedani","sequence":"additional","affiliation":[{"name":"Center for Health Policy & Health Services Research, Henry Ford Health System, Detroit, MI."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra B.","family":"Morissette","sequence":"additional","affiliation":[{"name":"Veterans Affairs VISN 17 Center of Excellence for Research on Returning War Veterans, Waco, TX, and Associate Professor, College of Medicine, Texas A&M Health Sciences Center."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"2019041211002934200_b1-0710728","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1159\/000225979","article-title":"The hippocampus and nucleus accumbens as potential therapeutic targets for neurosurgical intervention in schizophrenia","volume":"87","author":"Mikell","year":"2009","journal-title":"Stereotact Funct Neurosurg"},{"key":"2019041211002934200_b2-0710728","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1192\/apt.6.3.161","article-title":"Cognitive impairment in schizophrenia","volume":"6","author":"O\u2019Carroll","year":"2000","journal-title":"Adv Psychiatr Treat"},{"key":"2019041211002934200_b3-0710728","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-244X-5-26","article-title":"Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics","volume":"5","author":"Faries","year":"2005","journal-title":"BMC Psychiatry"},{"key":"2019041211002934200_b4-0710728","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/schbul\/sbp130","article-title":"The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009","volume":"36","author":"Kreyenbuhl","year":"2010","journal-title":"Schizophr Bull"},{"key":"2019041211002934200_b5-0710728","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/oxfordjournals.schbul.a007071","article-title":"The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003","volume":"30","author":"Lehman","year":"2004","journal-title":"Schizophr Bull"},{"key":"2019041211002934200_b6-0710728","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/oxfordjournals.schbul.a033302","article-title":"Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations","volume":"24","author":"Lehman","year":"1998","journal-title":"Schizophr Bull"},{"key":"2019041211002934200_b7-0710728","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1023\/A:1022369323451","article-title":"Patient, provider, and treatment factors associated with poor-quality care for schizophrenia","volume":"1","author":"Young","year":"1999","journal-title":"Ment Health Serv Res"},{"key":"2019041211002934200_b8-0710728","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements","volume":"36","author":"Buchanan","year":"2010","journal-title":"Schizophr Bull"},{"issue":"suppl 2","key":"2019041211002934200_b9-0710728","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia, second edition","volume":"161","author":"Lehman","year":"2004","journal-title":"Am J Psychiatry"},{"key":"2019041211002934200_b10-0710728","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/oxfordjournals.schbul.a007111","article-title":"The Texas medication algorithm project: clinical results for schizophrenia","volume":"30","author":"Miller","year":"2004","journal-title":"Schizophr Bull"},{"key":"2019041211002934200_b11-0710728","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.4088\/JCP.v68n1115","article-title":"The Texas medication algorithm project antipsychotic algorithm for schizophrenia: 2006 update","volume":"68","author":"Moore","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"2019041211002934200_b12-0710728","volume-title":"Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia","year":"2002"},{"issue":"suppl 11","key":"2019041211002934200_b13-0710728","first-page":"3","article-title":"The expert consensus guideline series. Treatment of schizophrenia 1999","volume":"60","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"2019041211002934200_b14-0710728","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1177\/0269881109104882","article-title":"Psychiatrists\u2019 use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years","volume":"24","author":"Patel","year":"2010","journal-title":"J Psychopharmacol"},{"key":"2019041211002934200_b15-0710728","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/11632020-000000000-00000","article-title":"Comparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us?","volume":"26","author":"Attard","year":"2012","journal-title":"CNS Drugs"},{"key":"2019041211002934200_b16-0710728","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.4088\/JCP.v65n1013","article-title":"Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998\u20132000","volume":"65","author":"Ganguly","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"2019041211002934200_b17-0710728","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1759-8893.2012.00083.x","article-title":"Payer types associated with antipsychotic polypharmacy in an ambulatory care setting","volume":"3","author":"Williams","year":"2012","journal-title":"J Pharm Health Serv Res"},{"key":"2019041211002934200_b18-0710728","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S1553-7250(08)34072-0","article-title":"When is antipsychotic polypharmacy supported by research evidence? Implications for QI","volume":"34","author":"Goren","year":"2008","journal-title":"Jt Comm J Qual Patient Saf"},{"key":"2019041211002934200_b19-0710728","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.schres.2006.02.023","article-title":"Long-term combination antipsychotic treatment in VA patients with schizophrenia","volume":"84","author":"Kreyenbuhl","year":"2006","journal-title":"Schizophr Res"},{"key":"2019041211002934200_b20-0710728","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/oxfordjournals.schbul.a006920","article-title":"Antipsychotic prescribing practices in Connecticut\u2019s public mental health system: rates of changing medications and prescribing styles","volume":"28","author":"Covell","year":"2002","journal-title":"Schizophr Bull"},{"key":"2019041211002934200_b21-0710728","doi-asserted-by":"crossref","first-page":"52","DOI":"10.7812\/TPP\/11-017","article-title":"Reducing antipsychotic polypharmacy among psychogeriatric and adult patients with chronic schizophrenia","volume":"15","author":"Goh","year":"2011","journal-title":"Perm J"},{"key":"2019041211002934200_b22-0710728","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1055\/s-0031-1286345","article-title":"Antipsychotic polypharmacy in inpatients with schizophrenia in Asia (2001\u20132009)","volume":"45","author":"Xiang","year":"2012","journal-title":"Pharmacopsychiatry"},{"key":"2019041211002934200_b23-0710728","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/oxfordjournals.schbul.a006912","article-title":"Combination antipsychotics: pros, cons, and questions","volume":"28","author":"Miller","year":"2002","journal-title":"Schizophr Bull"},{"key":"2019041211002934200_b24-0710728","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/01.pra.0000405368.20538.cd","article-title":"Antipsychotic polypharmacy among patients admitted to a geriatric psychiatry unit","volume":"17","author":"Dolder","year":"2011","journal-title":"J Psychiatr Pract"},{"key":"2019041211002934200_b25-0710728","first-page":"67","article-title":"Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia","volume":"6","author":"Loosbrock","year":"2003","journal-title":"J Ment Health Policy Econ"},{"key":"2019041211002934200_b26-0710728","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-244X-8-19","article-title":"Cost of antipsychotic polypharmacy in the treatment of schizophrenia","volume":"8","author":"Zhu","year":"2008","journal-title":"BMC Psychiatry"},{"key":"2019041211002934200_b27-0710728","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1365-2125.1995.tb05791.x","article-title":"Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden","volume":"40","author":"Kiivet","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"2019041211002934200_b28-0710728","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1365-2125.2004.02102.x","article-title":"Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia","volume":"58","author":"Sim","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"2019041211002934200_b29-0710728","first-page":"183","article-title":"Polypharmacy in psychiatry: a multistate comparison of psychotropic drug combinations","volume":"35","author":"Sheppard","year":"1974","journal-title":"Dis Nerv Syst"},{"key":"2019041211002934200_b30-0710728","first-page":"113","article-title":"Benchmarking the quality of schizophrenia pharmacotherapy: a comparison of the Department of Veterans Affairs and the private sector","volume":"6","author":"Leslie","year":"2003","journal-title":"J Ment Health Policy Econ"},{"key":"2019041211002934200_b31-0710728","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00005053-200004000-00003","article-title":"Benchmarking treatment of schizophrenia: a comparison of service delivery by the national government and by state and local providers","volume":"188","author":"Rosenheck","year":"2000","journal-title":"J Nerv Ment Dis"},{"key":"2019041211002934200_b32-0710728","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00019442-200002000-00003","article-title":"Schizophrenia and older adults. An overview: directions for research and policy","volume":"8","author":"Cohen","year":"2000","journal-title":"Am J Geriatr Psychiatry"},{"key":"2019041211002934200_b33-0710728","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa052827","article-title":"Risk of death in elderly users of conventional vs. atypical antipsychotic medications","volume":"353","author":"Wang","year":"2005","journal-title":"N Engl J Med"},{"key":"2019041211002934200_b34-0710728","unstructured":"Statistics NCfH. National Ambulatory Medical Care Survey 2008. ftp:\/\/ftp.cdc.gov\/pub\/Health_Statistics\/NCHS\/Dataset_Documentation\/NAMCS\/ (accessed 2008 Feb 6)."},{"key":"2019041211002934200_b35-0710728","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/CIRCOUTCOMES.108.801654","article-title":"The Cardiovascular Research Network: a new paradigm for cardiovascular quality and outcomes research","volume":"1","author":"Go","year":"2008","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2019041211002934200_b36-0710728","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3121\/cmr.2010.974","article-title":"Emerging frontiers in health care research and delivery: the 16th Annual HMO Research Network Conference, March 21\u201324, 2010, Austin, Texas","volume":"8","author":"Stevens","year":"2010","journal-title":"Clin Med Res"},{"key":"2019041211002934200_b37-0710728","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3121\/cmr.2013.1176.ps3-47","article-title":"PS3-47: Rural Health Research Initiative in the HMORN: a new scientific interest group","volume":"11","author":"Copeland","year":"2013","journal-title":"Clin Med Res"},{"key":"2019041211002934200_b38-0710728","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2019041211002934200_b39-0710728","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/00004479-200407000-00011","article-title":"Comorbidity assessments based on patient report: results from the Veterans Health Study","volume":"27","author":"Selim","year":"2004","journal-title":"J Ambul Care Manage"},{"key":"2019041211002934200_b40-0710728","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/1472-6963-9-127","article-title":"Patterns of primary care and mortality among patients with schizophrenia or diabetes: a cluster analysis approach to the retrospective study of health care utilization","volume":"9","author":"Copeland","year":"2009","journal-title":"BMC Health Serv Res"},{"key":"2019041211002934200_b41-0710728","unstructured":"Hing\n              E\n            ,CherryDK,WoodwellDA, Centers for Disease Control and Prevention. National Ambulatory Medical Care Survey: 2003 summary. www.cdc.gov\/nchs\/data\/ad\/ad365.pdf (accessed 2014 Jan 27)."},{"issue":"suppl 17","key":"2019041211002934200_b42-0710728","first-page":"19","article-title":"Unintended outcomes of Medicaid drug cost-containment policies on the chronically mentally ill","volume":"64","author":"Soumerai","year":"2003","journal-title":"J Clin Psychiatry"},{"issue":"6, pt 2","key":"2019041211002934200_b43-0710728","first-page":"335","article-title":"Effect of a medication copayment increase in veterans with schizophrenia","volume":"13","author":"Zeber","year":"2007","journal-title":"Am J Manag Care"},{"key":"2019041211002934200_b44-0710728","unstructured":"Shekelle\n              PG\n            ,AschS,GlassmanP, for Department of Veterans Affairs. Comparison of quality of care in VA and non-VA settings: a systematic review. www.ncbi.nlm.nih.gov\/books\/NBK49108\/pdf\/TOC.pdf (accessed 2014 Feb 27)."},{"issue":"11, pt 2","key":"2019041211002934200_b45-0710728","first-page":"861","article-title":"Problems due to medication costs among VA and non-VA patients with chronic illnesses","volume":"10","author":"Piette","year":"2004","journal-title":"Am J Manag Care"},{"key":"2019041211002934200_b46-0710728","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/01.mlr.0000108742.26446.17","article-title":"Health insurance status, cost-related medication underuse, and outcomes among diabetes patients in three systems of care","volume":"42","author":"Piette","year":"2004","journal-title":"Med Care"},{"key":"2019041211002934200_b47-0710728","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1176\/ps.2009.60.7.898","article-title":"Dropout from outpatient mental health care in the United States","volume":"60","author":"Olfson","year":"2009","journal-title":"Psychiatr Serv"},{"key":"2019041211002934200_b48-0710728","unstructured":"Watkins\n              KE\n            ,SmithB,PaddockSM, RAND Corporation. Program evaluation of VHA mental health services: Capstone report, 2011. www.rand.org\/content\/dam\/rand\/pubs\/technical_reports\/2011\/RAND_TR956.pdf (accessed 2014 Jan 27)."},{"issue":"5, pt 2","key":"2019041211002934200_b49-0710728","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1111\/j.1475-6773.2005.00448.x","article-title":"Measurement in Veterans Affairs health services research: veterans as a special population","volume":"40","author":"Morgan","year":"2005","journal-title":"Health Serv Res"},{"key":"2019041211002934200_b50-0710728","author":"Stock","journal-title":"Method of analysis as a factor in models of admission among veterans of Iraq and Afghanistan deployments"},{"key":"2019041211002934200_b51-0710728","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.schres.2012.10.015","article-title":"Interventions to reduce antipsychotic polypharmacy: a systematic review","volume":"143","author":"Tani","year":"2013","journal-title":"Schizophr Res"},{"key":"2019041211002934200_b52-0710728","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1176\/ps.49.2.196","article-title":"Compliance with medication regimens for mental and physical disorders","volume":"49","author":"Cramer","year":"1998","journal-title":"Psychiatr Serv"},{"key":"2019041211002934200_b53-0710728","doi-asserted-by":"crossref","first-page":"892","DOI":"10.4088\/JCP.v63n1007","article-title":"Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature","volume":"63","author":"Lacro","year":"2002","journal-title":"J Clin Psychiatry"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/71\/9\/728\/28372549\/ajhp0728.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,13]],"date-time":"2019-04-13T00:48:12Z","timestamp":1555116492000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/71\/9\/728\/5111256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,1]]},"references-count":53,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,5,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp130471","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,5,1]]},"published":{"date-parts":[[2014,5,1]]}}}